Commercial Immunoassays in Biomarkers Studies: Researchers Beware!

被引:24
作者
Rifai, Nader [1 ,2 ]
Watson, Ian D. [3 ]
Miller, W. Greg [4 ]
机构
[1] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA
[2] Childrens Hosp, Dept Pathol, Boston, MA 02115 USA
[3] Aintree Univ Hosp NHS Fdn Trust, Dept Clin Chem, Liverpool L9 7AL, Merseyside, England
[4] Virginia Commonwealth Univ, Dept Pathol, Richmond, VA USA
关键词
DISCOVERY;
D O I
10.1373/clinchem.2012.192351
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
100118 [医学信息学]; 100208 [临床检验诊断学];
摘要
引用
收藏
页码:1387 / 1388
页数:2
相关论文
共 6 条
[1]
[Anonymous], 2012, ELSEVIER SCI INT C S
[2]
[Anonymous], Research Portfolio Online Reporting Tools (RePORT). Date unknown
[3]
A recipe for disaster [J].
Git, Anna .
NATURE, 2012, 484 (7395) :439-440
[4]
Protein biomarker discovery and validation: the long and uncertain path to clinical utility [J].
Rifai, Nader ;
Gillette, Michael A. ;
Carr, Steven A. .
NATURE BIOTECHNOLOGY, 2006, 24 (08) :971-983
[5]
Advances in validation, risk and uncertainty assessment of bioanalytical methods [J].
Rozet, E. ;
Marini, R. D. ;
Ziemons, E. ;
Boulanger, B. ;
Hubert, Ph .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 55 (04) :848-858
[6]
Mass Spectrometry in Biomarker Applications: From Untargeted Discovery to Targeted Verification, and Implications for Platform Convergence and Clinical Application [J].
Smith, Richard D. .
CLINICAL CHEMISTRY, 2012, 58 (03) :528-530